Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6082 ARTÍCULOS , VIENDO DEL 3916 AL 3930

Overcoming Oxidative Stress in Parkinson's Disease: NADPH Oxidase 4 (NOX4) as a Potential Therapeutic Target

Xu X, Wang Q, Liu Z, Li J, Wang S, Qian L.

Antioxidants (Basel). 2026 May 1;15(5):571. doi: 10.3390/antiox15050571.

From phenotype to biology: a multi-modal roadmap of biofluid, tissue, imaging, and digital biomarkers in Parkinson's disease

Yu Z, Su D, Li S, Lin S, Ren K, Feng T.

Transl Neurodegener. 2026 May 28;15(1):25. doi: 10.1186/s40035-026-00558-0.

Advances in therapeutic hybrid neuromodulation for Parkinson's disease

Bano I, Jeevanandam J, Tsenov G.

3 Biotech. 2026 Jan;16(1):58. doi: 10.1007/s13205-025-04681-z. Epub 2026 Jan 5.

NRF2 at the crossroads of Parkinson's disease and aging: Mechanistic insights and translational perspectives

García-Yagüe AJ, Esteras N, Dinkova-Kostova AT, Rojo AI, Shiels PG, Dinnyes A, Tamas V, van Goor H, Lastres-Becker I.

Free Radic Biol Med. 2026 Mar 16;246:760-779. doi: 10.1016/j.freeradbiomed.2026.01.023. Epub 2026 Jan 13.

Mitochondrial dysfunction and disrupted neuronal lipid homeostasis in Parkinson's disease: Potential mechanisms and therapeutic implications

Quan Z, Ku CY, Xie T, Fok HT, Schweitzer D, Akefe IO.

Exp Neurol. 2026 Jun;400:115703. doi: 10.1016/j.expneurol.2026.115703. Epub 2026 Feb 26.

Circadian disruption and its clinical implications in Parkinson's disease: A Narrative review

Kataoka H, Saeki K, Sugie K, Obayashi K.

Sleep Med. 2026 Jul;143:108928. doi: 10.1016/j.sleep.2026.108928. Epub 2026 Mar 25.

Exercise suppresses apoptosis for alleviating Parkinson's disease: effects on pathophysiological molecular pathways

Chen J, Liu X, Wu Y, Wang C, Wang C.

Front Aging Neurosci. 2026 Mar 27;18:1810397. doi: 10.3389/fnagi.2026.1810397. eCollection 2026.

Reimagining the contribution of iron in Parkinson's disease

Serpa RO, Tufano E, Connor JR.

Neurobiol Dis. 2026 May 5;225:107434. doi: 10.1016/j.nbd.2026.107434. Online ahead of print.

Purinergic modulation in Parkinson's disease: the dual role of istradefylline in motor and cognitive outcomes

Rejili M, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Jabir MS, Shokr MM, Batiha GE.

Purinergic Signal. 2026 May 14;22(3):49. doi: 10.1007/s11302-026-10160-8.

Nonmotor Symptoms in Parkinson's Disease: Neurophysiology Biomarkers and Neuromodulation Approaches

Pathak N, Chen R, Chao A, Bick SK.

Stereotact Funct Neurosurg. 2026 May 21:1-14. doi: 10.1159/000551492. Online ahead of print.

Quantitative and Comparative Analysis of Dream Content in Parkinson's Disease Patients Undergoing Deep Brain Stimulation: A Pilot Study

Joswig H, Oreizi-Esfahani S, Medack S, Träger U, Staudt MD.

World Neurosurg. 2026 Mar;207:124816. doi: 10.1016/j.wneu.2026.124816. Epub 2026 Jan 17.

Long-term outcomes associated with istradefylline versus catechol-O-methyltransferase inhibitors in patients with Parkinson's disease: a nationwide real-world cohort study

Ju C, Kubota K, Xiong X, Sato T, Carroll C, Schrag A, Wei L, Foltynie T.

Parkinsonism Relat Disord. 2026 Mar;144:108211. doi: 10.1016/j.parkreldis.2026.108211. Epub 2026 Jan 27.

Decode the Ubiquitinome in Parkinson's Disease: From Pathological Aggregates to Targeted DUB Therapeutics

Yu X, Ni Q, Han L, Zhang S, Xu H, Xie J, Liu Y.

Neurosci Bull. 2026 Mar 28. doi: 10.1007/s12264-026-01613-6. Online ahead of print.

[Hypersexuality in Parkinson's Disease]

Kashihara K.

Brain Nerve. 2026 Jan;78(1):37-43. doi: 10.11477/mf.188160960780010037.

Advances in the pharmacological management of early motor manifestations of Parkinson's disease (PD)

Müller T, Kohlhepp W.

Expert Rev Neurother. 2026 Jun;26(6):547-554. doi: 10.1080/14737175.2026.2645845. Epub 2026 Mar 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias